8-K: Teva Pharmaceutical Reports Strong Q1 2024 Results Driven by Generics and AUSTEDO Growth

Teva's first quarter of 2024 saw a 5% revenue increase in local currency, fueled by generics and key product growth, with reaffirmed financial outlook for the year.

Summary

• Teva Pharmaceutical Industries Ltd. reported a 5% increase in revenue in local currency terms for the first quarter of 2024, reaching $3.8 billion.
• The growth was primarily driven by a 9% increase in the generics business globally and a 67% increase in AUSTEDO revenues in the U.S.
• AJOVY revenues also saw an 18% increase, reaching $113 million.
• The company reaffirmed its full-year 2024 financial outlook, projecting revenues between $15.7 and $16.3 billion, adjusted EBITDA between $4.5 and $5.0 billion, non-GAAP diluted EPS between $2.20 and $2.50, and free cash flow between $1.7 and $2.0 billion.
• Teva reported a GAAP loss per share of $0.12, but a non-GAAP diluted EPS of $0.48.
• The company's free cash flow for the quarter was $32 million, and cash flow used in operating activities was $124 million.
• Teva also announced positive Phase 3 efficacy results for olanzapine LAI (TEV 749) with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date.
• Recent FDA approvals of SIMLANDI and SELARSDI, biosimilars to Humira and Stelara, respectively, were also highlighted.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in key areas and reaffirmed guidance, but there are some concerns about the GAAP loss and cash flow.

Positives

• The generics business showed strong growth across all regions, increasing by 9% in local currency terms.
• AUSTEDO's growth in the U.S. was significant, with a 67% increase in revenue.
• AJOVY also demonstrated strong growth with an 18% increase in revenue.
• The company received FDA approvals for two biosimilars, SIMLANDI and SELARSDI.
• Phase 3 results for olanzapine LAI were positive, indicating a well-tolerated treatment option for schizophrenia.
• Teva reaffirmed its full-year 2024 financial outlook, demonstrating confidence in its performance.
• Non-GAAP gross profit margin increased to 51.4% in Q1 2024, compared to 49.1% in Q1 2023.
• Non-GAAP operating income increased to $892 million, representing a non-GAAP operating margin of 23.4%.

Negatives

• Teva reported a GAAP loss per share of $0.12 for the first quarter of 2024.
• Cash flow used in operating activities was $124 million.
• Operating loss in the first quarter of 2024 was $218 million, compared to an operating loss of $13 million in the first quarter of 2023.
• COPAXONE revenues in the United States decreased by 58% due to generic competition.
• Anda revenues decreased by 10% due to lower demand from seasonal and other market conditions.
• Net loss attributable to non-controlling interests was $280 million in the first quarter of 2024, compared to a net loss of $33 million in the first quarter of 2023.

Risks

• Teva faces substantial competition in the generic and innovative drug markets.
• The company is substantially dependent on its generic products.
• Delays in launching new generic products could impact revenue.
• Teva's substantial indebtedness may limit its ability to incur additional debt or make new investments.
• The company is subject to extensive pharmaceutical regulations.
• Teva faces risks related to legal and regulatory matters, including opioid litigation.
• The ongoing conflict in Israel could disrupt operations and facilities.
• The company is exposed to currency fluctuations and credit risks.
• There is a risk of potential impairments of long-lived assets.

Future Outlook

Teva reaffirmed its full-year 2024 financial outlook, projecting revenues between $15.7 and $16.3 billion, adjusted EBITDA between $4.5 and $5.0 billion, non-GAAP diluted EPS between $2.20 and $2.50, and free cash flow between $1.7 and $2.0 billion.

Management Comments

• Mr. Richard Francis, Teva's President and CEO, stated that Teva is off to a good start in 2024, with global revenues showing growth of 5% in local currency terms.
• Mr. Francis also highlighted the significant strides made in realizing the goals of the Pivot to Growth Strategy, including the progression of the innovative pipeline and recent FDA approvals.

Industry Context

Teva's results reflect a broader trend in the pharmaceutical industry where generic drug sales are a significant revenue driver, and biosimilars are gaining importance. The growth of AUSTEDO and AJOVY highlights the potential of innovative brands in the market. The company's focus on its Pivot to Growth strategy aligns with the industry's need for strategic portfolio management and innovation.

Comparison to Industry Standards

• Teva's 5% revenue growth in local currency terms is a positive sign, especially when compared to some of its generic competitors who may be facing pricing pressures.
• The 67% growth in AUSTEDO revenue is particularly strong, indicating successful commercialization and market penetration, which is a key metric for specialty pharmaceutical companies.
• The FDA approvals of SIMLANDI and SELARSDI position Teva well in the biosimilar market, which is a growing segment of the pharmaceutical industry, and is comparable to other companies such as Amgen and Sandoz who are also investing heavily in biosimilars.
• Teva's non-GAAP operating margin of 23.4% is a solid performance, but it is important to compare this to other large pharmaceutical companies such as Pfizer and Novartis to see how it stacks up against industry benchmarks.
• The company's free cash flow of $32 million is relatively low, and it will be important to monitor this metric in future quarters to ensure that the company is generating sufficient cash to support its operations and growth initiatives.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and reaffirmed financial outlook.
• Employees may be encouraged by the company's positive performance and strategic direction.
• Customers will benefit from the availability of new and innovative medicines.
• Suppliers may see increased demand for their products and services.
• Creditors will be reassured by the company's reaffirmed financial guidance and debt management efforts.

Next Steps

• Teva will continue to execute its Pivot to Growth strategy.
• The company will focus on expanding its innovative and biosimilar medicines pipeline.
• Teva plans to launch UZEDY in other countries around the world.
• The company intends to divest its API business by the first half of 2025.
• Teva will continue to monitor and manage its debt levels.
• The company will continue to progress its innovative pipeline, including olanzapine LAI.

Key Dates

Keywords

Teva, Pharmaceuticals, Generics, AUSTEDO, AJOVY, Biosimilars, SIMLANDI, SELARSDI, Olanzapine LAI, Financial Results, Q1 2024, Revenue, EBITDA, EPS, Free Cash Flow